Stem Cell-Mediated Gene Delivering for the Treatment of Cerebral Ischemia: Progress and Prospectives

Author(s): Chao Chen, Yongting Wang, Guo-Yuan Yang

Journal Name: Current Drug Targets

Volume 14 , Issue 1 , 2013

Become EABM
Become Reviewer
Call for Editor


Ischemic stroke is one of the leading causes of death and disability worldwide. There is no effective treatment for ischemic stroke apart from thrombolytic therapy, which has a narrow therapeutic time window. Gene therapy has proven to be effective in experimental stroke, but it suffers from disadvantages that limit its clinical application, such as difficulty in intracranial delivering of therapeutic genes, low efficacy in transfecting host cells and long-term expression of exogenous genes. Delivering therapeutic genes to the ischemic brain via stem cells is an alternative strategy of combined gene and stem cell therapy. There are advantages for stem cell-mediated gene delivery as opposed to direct gene transfer. In recent years, studies used stem cells that over-express different neurotrophic factors, such as BDNF, GDNT, or NT3, and found that the delivery of these genetically-modified stem cells to animal models of ischemic stroke is safe and effective, thus suggesting that stem cell-based gene therapy may be a promising treatment for stroke. This review summarizes the advantages and recent progress of stem cell-based gene therapy for ischemic stroke. We also discuss the relevant strategy for optimizing stem cell-based gene therapy and discuss the potential strategies for its future application.

Keywords: Embryonic stem cell, gene therapy, stem cell, ischemic stroke, mesenchymal stem cell, neural stem cell

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 28 December, 2012
Page: [81 - 89]
Pages: 9
DOI: 10.2174/1389450111314010009
Price: $65

Article Metrics

PDF: 35